Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. - Adams, S; Loi, S; Toppmeyer, D; Cescon, D W; Laurentiis, M De; Nanda, R; Winer, E P; Mukai, H; Tamura, K; Armstrong, A; Liu, M C; Iwata, H; et al. (Annals of Oncology, 2019)